Siltuximab to Be Evaluated for COVID-19 Associated ARDS in Phase 3 Trial
Siltuximab is currently marketed under the trade name Sylvant and is indicated for the treatment of multicentric Castleman’s disease.
Related Articles
FDA Grants Orphan Drug Status to Anti-Properdin Antibody for PNH
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway.
On-Body Infusor System for Repatha to Be Discontinued Soon
The Repatha Pushtronix System will be discontinued as of June 30, 2024.
Mpox At-Home Collection Kit Gets FDA’s Emergency Use Authorization
The kit includes a lesion swab, collection tube, and a return package to an authorized laboratory for analysis.
March 2024 Recap: Drug Pipeline Updates
The table below is a review of notable updates that occurred in March 2024 for investigational products in development.
MPR Weekly Dose Podcast #199
Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued…
FDA Clears Noninvasive Device for Generalized Anxiety Disorder
The treatment is delivered for a period of 30 minutes before bed.
Rezdiffra Now Available for Noncirrhotic NASH With Liver Fibrosis
Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network.
Undiagnosed Stroke Leads to Record-Breaking Verdict
At the appointment, Mr A complained of a persistent cough “for a couple of months” and difficulty breathing during the coughing fits.
FDA Approval Expands Use of Abecma for Multiple Myeloma
the approval allows patients with relapsed/refractory multiple myeloma to receive the T-cell therapy earlier than previously indicated.
MPR Weekly Dose Podcast #198
First prescription smartphone app is approved for major depressive disorder; Novel blood test to detect TBI; Zevtera has been approved for bloodstream infections; The Mpox…